[Effect of lanreotide on prolactin level in patients with pituitary mixed tumors]. / Influence du lanréotide sur la concentration sérique de prolactine chez les patients atteints de tumeurs somato-lactotropes.
Ann Endocrinol (Paris)
; 63(6 Pt 1): 532-5, 2002 Dec.
Article
in Fr
| MEDLINE
| ID: mdl-12527855
Acromegaly is a disease caused by a pituitary tumor (somatotropinoma) or by ectopic secretion of GH or IGF-1. About 15% of tumors secrete not only GH but PRL as well. Last time a lanreotide and an octreotide (the somatostatine analogues) are useful in the therapy of acromegaly. We observed the influence of the lanreotide on GH and prolactin. We noticed that the lanreotide caused not only serum level reduction of a growth hormone but also prolactine in patients with mixed pituitary tumors.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Peptides, Cyclic
/
Pituitary Neoplasms
/
Prolactin
/
Acromegaly
/
Somatostatin
/
Antineoplastic Agents
Type of study:
Observational_studies
/
Prognostic_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
Fr
Journal:
Ann Endocrinol (Paris)
Year:
2002
Document type:
Article
Affiliation country:
Poland
Country of publication:
France